EVLV — Evolv Technologies Holdings, Inc.

Thesis

Verdict: SPECULATIVE TURNAROUND / WATCH. Low-to-medium conviction — a catalyst-driven post-restatement turnaround in AI weapons detection, attractive on the recovery narrative but carrying a stacked risk profile (FTC consent order, fresh-from-restatement controls, single-program concentration, thin coverage). Evolv makes AI-powered touchless weapons-screening portals (Evolv Express) for stadiums, schools, hospitals, courts, and transit — a SaaS/subscription model (84% recurring) on top of a ~6,100-unit installed base that has scanned 3B+ people. The business is real and reaccelerating: Q3 2025 revenue $42.9M (+57% YoY), ARR $117.2M, Adjusted EBITDA turned meaningfully positive ($5.1M / 12%) for the first time, and the company guided Q4 2025 to positive operating cash flow.

The bull case is the recovery arc, not the multiple. The April 2025 (Mike Multibagger) pitch framed it as a clean catalyst chain: FTC cleared, accounting restatement nearly done, three quarters of earnings due by May 19 2025, ~40% ARR growth, 6,000 units deployed, management guiding to positive FCF by year-end, new leadership and IR resuming — a highly shorted name where delinquent-filer removal plus the earnings cadence could re-rate it. (Discrepancy flag: that pitch cites ~40% ARR growth; the Q3 2025 profile shows ARR +25% YoY to $117.2M — different dates and likely different bases, both retained.)

The bear case is structural overhang, not a broken business. A material revenue-recognition restatement (Q2 2022–Q2 2024) cost both the CEO and CFO their jobs; the new team is fresh and unproven through a full audit cycle. The FTC consent order permanently bans unsupported AI-accuracy claims — a reputational and marketing constraint, especially in K-12. Altman Z-Score 0.42 sits in the distress zone (offset by a debt-light net-cash balance sheet — a monitoring flag, not imminent distress). Coverage is thin (4 analysts) for a ~$925M cap, and short interest spiked +52% in the last two weeks of Dec 2025.

Price-target spread is wide and source-dependent: the Apr 2025 pitch targeted $4.5–6+ on peer multiples; Nov 2025 sell-side consensus is $9.13 avg (high $10.00 / low $7.50, +72% implied off ~$5.30). Keep both — different vintages, different methods.

⚠ Staleness flag (2026-06-02): this page's deep data is a Q3 2025 / early-March 2026 snapshot. The Q4/FY2025 print scheduled for March 10 2026 — the single most important near-term inflection (does operating cash flow actually turn positive?) — has since occurred and is not yet captured here. Run /filings EVLV to refresh before any decision.

Snapshot

One-liner: AI-powered touchless weapons-detection (Evolv Express) on a SaaS subscription model — a post-restatement, post-FTC turnaround re-accelerating toward cash-flow breakeven, with a real installed base but a stacked governance/regulatory risk profile.

• Ticker / exchange: EVLV on NASDAQ (NasdaqCM)
• Legal name: Evolv Technologies Holdings, Inc.; HQ Waltham, Massachusetts; founded July 2013 (co-founders Michael Ellenbogen, Anil Chitkara); public 2021 via SPAC merger (NewHold Investment Corp.); ~306 employees; evolv.com
• Sector / industry: Information Technology / Security & Detection Systems (GICS)
• Spot price (approx., Nov 2025 reference): ~$5.30; 52-wk range ~$3.50–$8.50 (estimated — verify on live quote, not confirmed in filings)
• Market cap: ~$925M | EV ~$912M
• Valuation: P/E N/M (net loss) | P/S (TTM) 6.8x | EV/Revenue 6.7x | Dividend none
• Shares: 174.62M outstanding; float 165.65M (94.9%); insiders 5.13%; institutions 68.74%
• Short interest: 9.97M shares / 6.02% of float / 3.91 days to cover; +51.8% increase Dec 15→31 2025 (build-up flag)
• Coverage: thin — 4 analysts (2 Strong Buy, 2 Buy, 0 Hold/Sell = Strong Buy consensus); avg PT $9.13 (high $10.00 / low $7.50), +72% implied off ~$5.30, last updated Nov 14 2025 (pre-Q4)
• Conviction: Low-to-medium — SPECULATIVE / WATCH

Business

What they do. Evolv makes AI-powered touchless weapons-detection systems — flagship Evolv Express® — that screen people for concealed firearms, IEDs, and tactical knives using digital sensors and machine learning, without requiring stops, item removal, or a traditional metal-detector portal. Targeted at high-throughput venues where speed and low friction matter: stadiums, schools, hospitals, courts, transit hubs. As of year-end 2024: ~6,100 units deployed, 1,000+ customers, 3B+ people scanned since 2019.

Business model. Primarily SaaS/subscription — multi-year recurring service contracts. Hardware is bundled or sold separately but increasingly subordinated to the subscription. Manufacturing is outsourced (no structural cost advantage).

Revenue segments (FY2024):

Segment	Revenue	% of Total	YoY
Recurring (subscription / services)	$87.4M	84%	+72%
Non-recurring (hardware / one-time)	$16.4M	16%	−43%
Total	$103.9M	100%	+31%

Geographic mix: predominantly US (>90% of revenue, estimated); international exists but is not a separately disclosed material segment. DHS SAFETY Act designation (QATT) applies to domestic deployments.

Key products:

• Evolv Express® — flagship AI walk-through weapons-detection portal; DHS SAFETY Act QATT designation
• Evolv eXpedite™ — higher-throughput variant; DHS Developmental Testing & Evaluation designation; targets large stadium/arena applications
• Evolv Insights — SaaS analytics layer (data, trends, reporting) on top of the installed base; higher-margin, early monetization

Competitive set. Direct: Xtract One Technologies (XIT.V, TSX-V — the most direct public comp; AI weapons detection for sports venues + K-12) · Athena Security (private; Austin, founded 2017) · CEIA (private, Italian; traditional high-sensitivity metal detectors, airports/prisons) · SoundThinking (SSTI; broader public-safety platform, weapons detection as part of a suite, less pure-play) · Neural Guard (private, early-stage). Traditional metal-detector OEMs (CEIA, Garrett, L3) still dominate airport/prison/courthouse; Evolv carves out the "frictionless venue" segment. Market share not publicly disclosed.

Moat. First-mover in AI walk-through screening; 3B+ scans of proprietary training data is a meaningful dataset moat (an indirect data network effect, though it does not lock in individual customers). DHS SAFETY Act QATT is a trust/procurement signal for government-adjacent buyers. Switching costs are moderate-to-high (multi-year contracts, on-site hardware integration, trained staff workflows). Brand was damaged in K-12 by the FTC action, partially offset by 92% retention post-cancellation window. No cost advantage (outsourced manufacturing); weak direct network effects. Porter snapshot: rivalry moderate-high, new-entrant threat moderate (replicable AI; barrier is dataset + DHS cert; defense primes like Leidos/SAIC could enter), buyer power moderate-high (sophisticated institutional procurement; FTC action empowered some exits), supplier power low-moderate, substitute threat moderate (cheaper metal detectors, "no screening," emerging AI camera detection).

Financials

TTM ≈ Q4 2024 – Q3 2025. Snapshot as of Q3 2025 / early March 2026 — see staleness flag in Thesis.

Metric	Value
Market cap	~$925M
Enterprise value	~$912M
Revenue (TTM)	$136.5M
Revenue growth (YoY)	~42% (9-mo 2025 basis); FY2024 +31%
Gross margin (TTM)	53.7% (FY2024: 57.1%)
Operating margin (TTM)	−42.2%
Net income / loss (TTM)	−$59.7M
EPS (TTM)	−$0.36
Adjusted EBITDA (TTM est.)	~$9–12M positive (high single-digit %, FY guidance)
Free cash flow (TTM)	Near breakeven; Q4 2025 guided to positive operating cash flow
Cash & marketable securities	$56.2M (Sept 30 2025)
Total debt	$42.4M
Net cash	~$13.8M
P/S (TTM)	6.8x
EV / Revenue	6.7x
ARR	$117.2M (Q3 2025, +25% YoY)
RPO (backlog)	$266.7M (year-end 2024)
Units deployed	~6,100 (year-end 2024)

⚠ Altman Z-Score 0.42 — bankruptcy-risk zone per stockanalysis.com. Context: reflects cumulative net losses; company is debt-light with net cash. Treat as a monitoring flag, not imminent distress.

Profitability arc. GAAP still loss-making (−$59.7M TTM, operating margin −42.2%), but the trajectory is the story: Adjusted EBITDA turned positive, net loss narrowed to −$1.8M in Q3 2025, and Q4 2025 was guided to positive operating cash flow. The GAAP-to-adjusted gap includes meaningful SBC and amortization. SBC dilution is real at this loss stage — shares outstanding grew +6.41% YoY. If growth decelerates before FCF self-sufficiency, a dilutive raise is possible.

Growth drivers. ARR ramp (subscription visibility); new verticals (healthcare — named AHA Preferred Physical Security Provider, ~6,000 US hospitals as channel; transit, courts); IP licensing ($3.0M deal in Q3 2025 — first notable monetization of the tech stack beyond hardware); Evolv Insights analytics (higher-margin software); eXpedite™ throughput line; early-stage international optionality. No material M&A disclosed or rumored.

Industry landscape

AI weapons-detection / security-screening — a niche carved out of the traditional metal-detector market by frictionless, high-throughput AI screening. No dedicated sector page in the vault yet; if one is created, link up here (e.g. security-detection). Adjacent public names for landscape context: Xtract One (XIT.V), SoundThinking (SSTI), and the entrenched metal-detector OEMs (CEIA, Garrett, L3).

Management

Leadership.

Role	Name	Tenure / Background
CEO & President	John Kedzierski	Since Dec 2024. 23+ yrs at Motorola Solutions, last as SVP Global Enterprise Sales. Replaced Peter George (departed Oct 2024).
CFO	Chris Kutsor	Since Apr 2025. Prior CFO/COO at Kin + Carta Plc (UK-listed digital consultancy); led its PE sale in 2024.
Chief Innovation Officer & Director	Michael Ellenbogen	Co-founder (2013); Head of Advanced Technology since Jan 2020. Original inventor; deep institutional knowledge.
SVP Finance & IR	Brian Norris	Head of investor relations.

Board (notable): Kevin Charlton (director since Jul 2021; Chair of Compensation & Investment Committees); Richard Shapiro (independent, appointed Feb 3 2025 — recent); Michael Ellenbogen (co-founder/CIO).

Governance. Insider ownership 5.13% (low); institutional 68.74%. No dual-class shares identified (standard Class A common). Staggered board not confirmed; no poison pill identified. SBC dilution meaningful at the loss stage (shares +6.41% YoY). No significant insider open-market buying flagged as of Q3 2025; both CEO (Dec 2024) and CFO (Apr 2025) are recent appointees — comp-linked equity grants expected but not yet confirmed as significant purchases. No 13D/13G activist filings identified; institutional base broadly distributed.

⚠ Governance flag — restatement. Evolv restated financials Q2 2022 – Q2 2024 (filed April 2025); root cause was premature/incorrectly recognized revenue on certain sales. Both CEO and CFO were replaced in the wake of it. New management inherited a broken revenue-recognition process; controls adequacy is not yet proven through a full audit cycle. Material governance event — monitor.

Catalysts & risks

Catalysts.

• Q4/FY2025 results (March 10 2026, after market close) — the key near-term inflection: does operating cash flow actually turn positive? (Has since occurred as of 2026-06-02 and is not yet captured here — refresh.)
• Delinquent-filer status removal + restored earnings cadence + IR resumption (core of the Apr 2025 turnaround pitch)
• ARR ramp continuing; FY guidance raised to $142–145M (+37–40%) at Q3
• Healthcare channel via AHA preferred-partner status (~6,000 US hospitals)
• IP licensing as a new revenue line ($3.0M Q3 2025 first deal)
• Short-squeeze optionality (highly shorted; new leadership) — the original pitch's setup
• eXpedite™ throughput line into large stadium/arena applications

Risks (structured):

1. FTC consent order (active, High) — Nov 2024 action alleging false/misleading claims on detection accuracy, false-alarm rates, labor savings; order finalized March 2025 permanently bans unsupported AI-capability claims. No monetary penalty; 92% of eligible K-12 customers stayed. But it constrains marketing, creates reputational overhang (especially K-12), and could resurface if real-world performance falls short.
2. Restatement / revenue-recognition controls (High) — Q2 2022–Q2 2024 restated; CEO + CFO both replaced; new team unproven through a full audit cycle.
3. Technology performance / false-negative liability (High) — FTC case stemmed partly from real incidents of weapons passing undetected (including at schools). A high-profile security failure at an Evolv-screened venue would be catastrophic to brand and could trigger material legal liability, regulatory action, and contract-termination waves.
4. Competition / commoditization (Medium-High) — well-funded private entrants and potential defense-prime entry; if detection algos commoditize, differentiation narrows to brand + installed-base lock-in.
5. Customer concentration / churn (Medium) — $3.0M from a single largest customer order in Q3 2025; K-12 contracts impaired by the FTC settlement; multi-year contracts lock pricing that may lag cost inflation.
6. Path to profitability / cash burn (Medium-High) — GAAP losses still large (−$59.7M TTM); Q4 2025 operating-cash-flow turn is the test; deceleration before self-sufficiency could force a dilutive raise.
7. Short-interest build (flag) — +52% in two weeks (Dec 15→31 2025), possibly signaling concern ahead of March 10 earnings.

Valuation / DCF

No DCF modeled. Multiples-only, and the P/S/EV-Rev figures are clean (P/S 6.8x, EV/Rev 6.7x; P/E N/M on losses). The valuation question is entirely about which earnings/cash-flow base you underwrite as the company crosses breakeven.

Price-target range — keep both vintages, they disagree:

• Apr 2025 (Mike Multibagger) pitch: $4.5–6+ on peer multiples — a turnaround/recovery frame.
• Nov 2025 sell-side consensus (4 analysts): avg $9.13, high $10.00, low $7.50, +72% implied off ~$5.30; last updated Nov 14 2025 (pre-Q4). Thin coverage — consensus may be skewed by the small sample.

Decision log

2026-06-02 — Consolidated (FOLD of evlv-profile.md, dated 2026-03-02/Q3-2025 data, into the canonical tracking page). Verdict: SPECULATIVE TURNAROUND / WATCH, low-to-medium conviction. A real, re-accelerating business (Q3 2025 +57% revenue, Adj. EBITDA positive, Q4 OCF-positive guide) wrapped in a stacked risk profile (FTC consent order, fresh-from-restatement controls, Z-Score 0.42, thin coverage). Two discrepancies retained and flagged: (i) ARR growth ~40% (Apr 2025 pitch) vs +25% YoY (Q3 2025 profile); (ii) PT $4.5–6+ (Apr 2025 pitch) vs $7.50–10.00 sell-side (Nov 2025). The March 10 2026 Q4/FY print — the cash-flow-breakeven test — has passed and is not yet captured; refresh via /filings EVLV before acting.

2026-05-31 (prior canonical entry) — TRACKING. Auto-maintained from the Apr 2025 Defense-drop pitch: catalyst-driven turnaround (FTC cleared, restatement nearly done, three quarters of earnings due by May 19 2025, 40% ARR growth, 6,000 units, positive-FCF-by-year-end guide, new leadership/IR resuming, short-squeeze setup). Pitch confirmed the core bull points: delinquent-filer resolution, ARR growth, PT $4.5–6+, short squeeze, leadership upgrade.

2026-03-02 (profile) — established the fundamental base: ~6,100 units, 84% recurring revenue, FY2024 $103.9M (+31%), TTM $136.5M (+42% 9-mo basis), ARR $117.2M, net loss −$59.7M, net cash ~$13.8M. Flagged FTC consent order, restatement, and Z-Score 0.42 as the three primary overhangs.

Sources

Fragments folded into this canonical page (consolidated 2026-06-02; original archived to _migration-archive/2026-06-02/EVLV/): evlv-profile.md (/profile, 2026-03-02, Q3 2025 data). The prior tracking-page body (Apr 2025 pitch auto-note) is retained inline above.

Filings / earnings history: evlv-filings (stub — run /filings EVLV to populate).

Pitch source: EVLV-Pitch-MultiMon-Apr2025 · dropfile://Defense/EVLV/Mike Multibagger_EVLV - Pitch (Apr 2025).pdf

Key external sources: Evolv Q3 2025 Earnings (BusinessWire) · FY2024 Results & Restatement (Evolv IR) · CEO Appointment (BusinessWire) · CFO Appointment (Evolv) · FTC Action (FTC.gov) · FTC Settlement Resolution (Evolv IR) · 92% Customer Retention (Evolv) · Statistics (StockAnalysis) · Analyst Forecast (StockAnalysis) · Q4 Results Date (Evolv IR) · Competitors (CBInsights)